Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mast-Cell Stabilizing Effects of Olopatadine
NCT00389025Phase 4Completed
- Sponsor
- Alcon Inc.
- Start
- Oct 2006
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of olopatadine in allergic conjunctivitis (AC), sponsored by Alcon Inc. Primary endpoint: Tear histamine. Started Oct 2006; status: completed.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT00389025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389025.